Halozyme Therapeutics (HALO) Q3 FY2026 earnings: revenue $493 million, up 39.2% on the year

Halozyme Therapeutics, Inc. (HALO) reported revenue of $493 million for Q3 FY2026, the quarter ended 30 September 2026, up 39.2% on the same quarter a year earlier. Net income was $247 million, up 41.0% on the year, and diluted earnings per share $2.01. The figures are the company's own, from the 10-Q it filed with the SEC on 5 November 2026.

Revenue

$493 million

+39.2% on the year · +2.5% on the quarter

Q4 FY2024Q3 FY2026

Operating margin

59.8%

61.5% a year earlier

Q4 FY2024Q3 FY2026

Net income

$247 million

+41.0% on the year · +7.5% on the quarter

Q4 FY2024Q3 FY2026

Diluted EPS

$2.01

+40.6% on the year · +5.8% on the quarter

Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 4 raised.

Total revenue up 39%: Total revenue was $493.0 million, up from $354.3 million, primarily from royalty revenue growth and higher product sales.
Royalties rose 44% to $341 million: Royalty revenue was $341.0 million, up from $236.0 million, driven mainly by partner products launched since 2020, including VYVGART Hytrulo, DARZALEX SC and Phesgo.
Argenx and Incyte deals expanded: Agreements with argenx and Incyte added targets for ENHANZE evaluation. Incyte also expanded to evaluate a SC formulation of axatilimab, with an upfront payment.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Revenue	493	481	354	+2.5%	+39.2%
Cost of revenue	82.5	79.2	55.2	+4.2%	+49.3%
Gross profit	410	402	299	+2.2%	+37.3%
Gross margin	83.3%	83.5%	84.4%
Research and development	27.8	27.7	17.3	+0.4%	+61.0%
Selling, general and administrative	58.2	57.0	46.1	+2.2%	+26.4%
Operating income	295	288	218	+2.5%	+35.4%
Operating margin	59.8%	59.8%	61.5%
Interest expense	6.0	5.6	4.3	+8.2%	+40.7%
Pre-tax income	291	285	219	+2.0%	+32.7%
Income tax	43.6	55.0	43.7	-20.7%	-0.3%
Effective tax rate	15.0%	19.3%	20.0%
Net income	247	230	175	+7.5%	+41.0%
Net margin	50.1%	47.8%	49.5%
Diluted EPS	$2.01	$1.90	$1.43	+5.8%	+40.6%

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Operating cash flow	258	241	179	+7.2%	+44.6%
Capital expenditure	3.0	4.2	3.0	-26.9%	+0.7%
Free cash flow	255	237	176	+7.8%	+45.4%
Free cash flow margin	51.8%	49.2%	49.6%
Cash from investing	20.9	-62.7	202		-89.6%
Cash from financing	588	-326	-22.4
Depreciation and amortisation	4.7	4.5	2.7	+4.4%	+74.1%
Share-based compensation	16.8	17.7	12.2	-5.1%	+38.2%
Buybacks	67.3	n/a	38.9		+73.0%
Diluted shares, weighted	123m	121m	122m	+1.2%	+0.2%
Shares outstanding at period end	114m	114m	118m	-0.1%	-3.1%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Shareholders' equity	-55.2	144	504
Debt	3,250	2,147	1,511	+51.4%	+115.1%
Other liabilities	278	287	207	-3.1%	+34.7%
Total liabilities and equity	3,473	2,577	2,221	+34.8%	+56.4%
Fixed assets	51.2	49.8	40.6	+2.9%	+26.2%
Goodwill	582	582	417	0.0%	+39.6%
Intangible assets	893	922	349	-3.2%	+156.2%
Securities held for sale or to maturity	44.4	67.9	282	-34.6%	-84.3%
Cash and equivalents	1,030	163	420	+531.4%	+145.4%
Receivables	519	453	344	+14.4%	+51.0%
Inventory	133	137	186	-3.3%	-28.6%
Other assets	222	202	184	+9.8%	+20.6%
Total assets	3,473	2,577	2,221	+34.8%	+56.4%

Questions

What was Halozyme Therapeutics' revenue in Q3 FY2026?

Halozyme Therapeutics (HALO) reported revenue of $493 million for Q3 FY2026, the quarter ended 30 September 2026, up 39.2% on the same quarter a year earlier.

How much did Halozyme Therapeutics earn in Q3 FY2026?

Net income for Q3 FY2026 was $247 million, up 41.0% on the year, and diluted earnings per share $2.01.

When did Halozyme Therapeutics report Q3 FY2026 results?

Halozyme Therapeutics filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 5 November 2026.

Quarterly results, the last 20 quarters

	Q4 FY2021 *	Q1 FY2022	Q2 FY2022	Q3 FY2022	Q4 FY2022 *	Q1 FY2023	Q2 FY2023	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	102	117	152	209	181	162	221	216	230	196	231	290	298	265	326	354	452	377	481	493
Cost of revenue	21.6	15.9	33.9	47.3	42.1	35.2	50.1	54.8	52.3	28.3	39.6	49.4	42.1	48.4	46.4	55.2	78.8	79.2	79.2	82.5
Gross profit	80.4	101	118	162	139	127	171	161	178	168	192	241	256	216	279	299	373	297	402	410
Gross margin	79%	86%	78%	77%	77%	78%	77%	75%	77%	86%	83%	83%	86%	82%	86%	84%	83%	79%	84%	83%
R&D	10.1	11.9	15.5	16.7	22.6	18.0	19.7	17.3	21.3	19.1	21.0	18.5	20.4	14.8	17.5	17.3	31.9	25.6	27.7	27.8
SG&A	13.8	13.8	57.5	34.5	37.7	37.4	38.9	35.3	37.6	35.1	35.7	41.2	42.2	42.4	41.6	46.1	77.0	57.9	57.0	58.2
Operating income	56.5	75.7	34.1	83.3	74.5	53.8	94.5	88.3	101	95.5	117	163	176	142	202	218	-92.9	185	288	295
Operating margin	55%	65%	22%	40%	41%	33%	43%	41%	44%	49%	51%	56%	59%	53%	62%	62%	-21%	49%	60%	60%
Interest expense	2.1	1.8	3.1	7.5	4.6	4.5	4.5	4.5	5.2	4.5	4.5	4.5	4.5	4.5	4.4	4.3	4.9	5.5	5.6	6.0
Pre-tax income	54.8	74.4	30.0	73.7	70.8	52.2	93.2	102	101	96.0	118	165	178	144	205	219	-101	180	285	291
Tax rate	-22%	19%	24%	16%	18%	24%	20%	20%	16%	20%	21%	17%	23%	18%	19%	20%	n/a	17%	19%	15%
Net income	66.8	60.1	22.7	61.6	57.7	39.6	74.8	81.8	85.4	76.8	93.2	137	137	118	165	175	-142	150	230	247
Net margin	65%	51%	15%	29%	32%	24%	34%	38%	37%	39%	40%	47%	46%	45%	51%	49%	-31%	40%	48%	50%
Diluted EPS	$0.45	$0.43	$0.16	$0.44	$0.42	$0.29	$0.56	$0.61	$0.65	$0.60	$0.72	$1.05	$1.06	$0.93	$1.33	$1.43	-$1.20	$1.22	$1.90	$2.01
Operating cash flow	82.5	47.8	40.2	69.6	82.5	87.0	66.8	132	102	129	55.8	115	178	154	99.7	179	219	180	241	258
Capital expenditure	0.2	0.5	1.0	1.0	2.3	11.4	n/a	2.9	2.6	3.5	2.6	1.5	3.1	0.9	1.6	3.0	1.4	3.7	4.2	3.0
Free cash flow	82.4	47.3	39.3	68.6	80.1	75.6	n/a	129	99.8	126	53.2	114	175	153	98.1	176	218	176	237	255
Buybacks	160	0.0	0.0	200	0.0	150	0.0	0.0	252	0.0	0.0	0.0	250	n/a	n/a	38.9	n/a	n/a	n/a	67.3
Shares outstanding	137m	138m	138m	135m	135m	132m	132m	132m	127m	127m	127m	127m	123m	123m	118m	118m	118m	119m	114m	114m
Filing	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 5 November 2026: the filing.